SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Caribou Biosciences Q3 Revenue Declines; Company to Discontinue Lead Clinical Program

Caribou Biosciences reported a decline in Q3 revenue and said it will discontinue its lead clinical program.

CRBU
SquawkNews Desk

OverviewOutlookResult DriversCompany press release:Key DetailsAnalyst CoverageReuters Recommended ReadsFor questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.(This story was created using…

Related stories

Eton Pharmaceuticals Reports Quarterly Results for Period Ended September 30 M impact | EQUITY | Nov 05, 2026, 11:28 PM UTC Astrana Health Reports Quarterly Results for Period Ended September 30 LSEG’s machine-generated earnings summary covers Astrana Health’s quarter ended September 30. M impact | EQUITY | Nov 05, 2026, 11:28 PM UTC RenovoRx reports quarterly results for period ended September 30 A machine-generated LSEG summary reports RenovoRx results for the quarter ended September 30; the supplied text contains no figures. M impact | EQUITY | Nov 05, 2026, 11:28 PM UTC Frasers Logistics & Commercial Trust Full-Year Revenue Rises The Singapore trust reported higher full-year revenue, citing rental growth and acquisitions. M impact | EQUITY | Nov 05, 2026, 11:28 PM UTC Nutex Health reports quarterly results for period ended September 30 The LSEG-generated summary provides no results figures in the available text. M impact | EQUITY | Nov 05, 2026, 11:26 PM UTC Aldeyra Therapeutics Reports Quarterly Results Through September 30 A machine-generated LSEG earnings summary covers the quarter ended September 30. M impact | EQUITY | Nov 05, 2026, 11:25 PM UTC